PURPOSE: Members of the SPAN-X (sperm protein associated with the nucleus mapped to the X chromosome) family of cancer-testis antigens are promising targets for tumor immunotherapy because they are normally expressed exclusively during spermiogenesis on the adluminal side of the blood-testis barrier, an immune privileged compartment. EXPERIMENTAL DESIGN AND RESULTS: This study analyzed the human SPANX genomic organization, as well as SPAN-X mRNA and protein expression in somatic and cancer cells. The SPANX family consists of five genes, one of which is duplicated, all located in a gene cluster at Xq27.1. From the centromere, the arrangement of the five SPANX genes mapped on one contiguous sequence is SPANXB, -C, -A1, -A2, and -D. Reverse transcription-PCR analyses demonstrated expression of SPAN-X mRNA in melanoma and ovarian cell lines, and virtual Northern analysis established SPANX gene expression in numerous cancer cell lines. Immunoblot analysis using polyclonal antisera raised against recombinant SPAN-X confirmed the translation of SPAN-X proteins in melanoma and ovarian tumor cell lines. The immunoreactive proteins migrated between M(r) 15,000 and M(r) 20,000 similar to those observed in spermatozoa. Immunoperoxidase labeling of melanoma cells and tissue sections demonstrated SPAN-X protein localization in the nucleus, cytoplasm, or both. Ultrastructurally, in melanoma cells with nuclear SPAN-X, the protein was associated with the nuclear envelope, a localization similar to that observed in human spermatids and spermatozoa. Significantly, the incidence of SPAN-X-positive immunostaining was greatest in the more aggressive skin tumors, particularly in distant, nonlymphatic metastatic melanomas. CONCLUSIONS: The data herein suggest that the SPAN-X protein may be a useful target in cancer immunotherapy.
PURPOSE: Members of the SPAN-X (sperm protein associated with the nucleus mapped to the X chromosome) family of cancer-testis antigens are promising targets for tumor immunotherapy because they are normally expressed exclusively during spermiogenesis on the adluminal side of the blood-testis barrier, an immune privileged compartment. EXPERIMENTAL DESIGN AND RESULTS: This study analyzed the humanSPANX genomic organization, as well as SPAN-X mRNA and protein expression in somatic and cancer cells. The SPANX family consists of five genes, one of which is duplicated, all located in a gene cluster at Xq27.1. From the centromere, the arrangement of the five SPANX genes mapped on one contiguous sequence is SPANXB, -C, -A1, -A2, and -D. Reverse transcription-PCR analyses demonstrated expression of SPAN-X mRNA in melanoma and ovarian cell lines, and virtual Northern analysis established SPANX gene expression in numerous cancer cell lines. Immunoblot analysis using polyclonal antisera raised against recombinant SPAN-X confirmed the translation of SPAN-X proteins in melanoma and ovarian tumor cell lines. The immunoreactive proteins migrated between M(r) 15,000 and M(r) 20,000 similar to those observed in spermatozoa. Immunoperoxidase labeling of melanoma cells and tissue sections demonstrated SPAN-X protein localization in the nucleus, cytoplasm, or both. Ultrastructurally, in melanoma cells with nuclear SPAN-X, the protein was associated with the nuclear envelope, a localization similar to that observed in human spermatids and spermatozoa. Significantly, the incidence of SPAN-X-positive immunostaining was greatest in the more aggressive skin tumors, particularly in distant, nonlymphatic metastatic melanomas. CONCLUSIONS: The data herein suggest that the SPAN-X protein may be a useful target in cancer immunotherapy.
Authors: Natalay Kouprina; Nicholas C O Lee; Adam Pavlicek; Alexander Samoshkin; Jung-Hyun Kim; Hee-Sheung Lee; Sudhir Varma; William C Reinhold; John Otstot; Greg Solomon; Sean Davis; Paul S Meltzer; Johanna Schleutker; Vladimir Larionov Journal: Genes Chromosomes Cancer Date: 2012-06-26 Impact factor: 5.006
Authors: Natalay Kouprina; Adam Pavlicek; Vladimir N Noskov; Greg Solomon; John Otstot; William Isaacs; John D Carpten; Jeffrey M Trent; Joanna Schleutker; J Carl Barrett; Jerzy Jurka; Vladimir Larionov Journal: Genome Res Date: 2005-11 Impact factor: 9.043
Authors: Bertrand Fabre; Yongmei Feng; Ikrame Lazar; Ali Khateb; Patrick Turko; Julia M Martinez Gomez; Dennie T Frederick; Mitchell P Levesque; Lea Feld; Gao Zhang; Tongwu Zhang; Brian James; Jeny Shklover; Emily Avitan-Hersh; Ido Livneh; Marzia Scortegagna; Kevin Brown; Ola Larsson; Ivan Topisirovic; Haguy Wolfenson; Meenhard Herlyn; Keith Flaherty; Reinhard Dummer; Ze'ev A Ronai Journal: Mol Cancer Res Date: 2020-06-22 Impact factor: 5.852
Authors: Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett Journal: Cancer Biol Ther Date: 2017-05-17 Impact factor: 4.742
Authors: Natalay Kouprina; Michael Mullokandov; Igor B Rogozin; N Keith Collins; Greg Solomon; John Otstot; John I Risinger; Eugene V Koonin; J Carl Barrett; Vladimir Larionov Journal: Proc Natl Acad Sci U S A Date: 2004-02-18 Impact factor: 11.205
Authors: Giovanni Almanzar; Purevdorj B Olkhanud; Monica Bodogai; Chiara Dell'agnola; Dolgor Baatar; Stephen M Hewitt; Claudio Ghimenton; Mohan K Tummala; Ashani T Weeraratna; Keith Sean Hoek; Natalay Kouprina; Vladimir Larionov; Arya Biragyn Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531